Summary
Eli Lilly and Company (LLY) filed an 8-K on April 28, 2022, to report its financial results for the quarter ended March 31, 2022. The report primarily incorporates by reference a press release, dated April 28, 2022, which contains the detailed financial outcomes and operational updates for the period. Investors should refer to the attached Exhibit 99.1 for the specific figures, including revenue, earnings, and any forward-looking guidance. While this 8-K filing itself is brief and serves to officially attach the earnings press release, the substance of the company's performance and outlook for the first quarter of 2022 is contained within that press release. Investors seeking to understand Lilly's financial condition and results of operations for the specified quarter need to examine the detailed information provided in Exhibit 99.1. This includes key financial metrics and any business developments announced by the company.
Key Highlights
- 1The 8-K filing announces Eli Lilly's financial results for the first quarter ended March 31, 2022.
- 2The primary content of the filing is Exhibit 99.1, a press release dated April 28, 2022.
- 3This press release contains the detailed financial results of operations and financial condition for the quarter.
- 4The filing notes that the information furnished is not deemed 'filed' for purposes of Section 18 of the Exchange Act, limiting liability.
- 5Investors are directed to the attached press release (Exhibit 99.1) for specific financial performance details.
- 6The filing also lists Exhibit 104 as the Cover Page Interactive Data File.